← All trials
NCT06808932
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2025
- Primary completion
- May 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Feb 5, 2025
- Last posted
- May 22, 2025
- Enrollment
- 48
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute on Drug Abuse (NIDA)Lead sponsor
- Altasciences Company Inc.Collaborator
- National Institute on Drug Abuse (NIDA)Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.